|
|||||
|
|
Optimal design and endpoint of clinical trials using immune checkpoint blocking agents |
|
| Authors: | Bhumsuk Keam Hun Jung Byung Ho Nam |
| Affiliation: | 1. Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea;2. Merck Sharp &3. Dohme, Seoul, Republic of Korea;4. National Cancer Center, Goyang, Republic of Korea |
| Abstract: | |
| Keywords: | Immune checkpoint blocking agents PD-1 PD-L1 endpoint clinical trial design |